Neurorehabilitation News

A study published recently in Nature found that hyperbaric oxygen therapy led to positive results for cognition and functionality for those with long COVID.

Vigil Neuroscience Inc. has announced positive interim data from a phase 2 proof-of-concept clinical trial of a monoclonal antibody to treat those suffering from adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Long-term treatment with psychedelics holds the potential to transform the health care industry through millions in savings, according to an expert at a congressional briefing hosted by Johns Hopkins University.

A United Kingdom-based biotech company has announced a global licensing agreement with a California pharma firm to research and develop drug candidates targeting two different ion channel targets associated with neurological disorders.

Neural markers can reliably distinguish mania/hypomania-specific risk from depression-specific risk in young adults, according to a study published in JAMA Psychiatry.

The Engelstad Foundation has provided a $1.5 million grant to Wave Neuroscience in support of the company’s ongoing phase 2 clinical trial to develop and validate innovative treatments for post-traumatic stress disorder and traumatic brain injury.

As November is National Epilepsy Awareness Month, Healio has gathered the most recent top stories about the condition that affects 3.4 million Americans each year.

Injections of botulinum toxin were associated with greater improvements in isolated and essential head tremor at 18 weeks compared with placebo, according to data from a randomized trial published in The New England Journal of Medicine.

A nonprofit focused on treatments and cures for Charcot-Marie-Tooth disease will partner with a biotechnology firm to advance a novel intrathecal miRNA therapy to address CMT type 1a in adults with the condition.

In adults with epilepsy, treatment with a novel, oral adjunctive therapeutic significantly reduced monthly occurrence of focal-onset seizures across three doses compared with placebo, according to research in JAMA Neurology.